A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' BTDS) And Placebo In Patients With Postherpetic Neuralgia.

Trial Profile

A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' BTDS) And Placebo In Patients With Postherpetic Neuralgia.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Acronyms ASSET-PHN
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2013 Planned number of patients changed from 120 to 124 as reported by Australian New Zealand Clinical Trials Registry.
    • 30 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top